Loading...
•
Jun 30, 2023
Generation Bio Q2 2023 Earnings Report
Generation Bio's financial performance declined in Q2 2023 with reduced R&D spending but increased G&A expenses, while collaboration revenue was recognized.
Key Takeaways
Generation Bio reported a net loss of $31.1 million, or $0.47 per share, for the second quarter of 2023. The company's cash position remains strong at $314.1 million, expected to fund operations into 2025. They are focused on demonstrating Factor VIII expression in non-human primates for hemophilia A program.
Cash, cash equivalents, and marketable securities totaled $314.1 million as of June 30, 2023.
Research and development expenses were $21.8 million for the quarter ended June 30, 2023.
General and administrative expenses were $13.0 million for the quarter ended June 30, 2023.
Net loss was $31.1 million, or $0.47 basic and diluted net loss per share, for the quarter ended June 30, 2023.
Revenue by Segment
Forward Guidance
The company is focused on demonstrating Factor VIII expression in non-human primates for its hemophilia A program and continued development of in-vivo targeting to immune cells with its stealth ctLNPs. Its cash position is expected to fund operations into 2025.
Positive Outlook
- Demonstrating Factor VIII expression in non-human primates for hemophilia A program
- Continued development of in-vivo targeting to immune cells with stealth ctLNPs
- Cash position expected to fund operations into 2025
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...